PDCD1 and melanoma: Anti-PD1 significantly delayed (p = 0.04) the progression of YUMMER1.7 melanoma xenografts compared to the isotype group, with a significant difference between groups upon day 9 after treatment initiation, as shown in Figure 1B,C.